A New Drug for Relapsed/Refractory Myeloma Patients: Melflufen image

A New Drug for Relapsed/Refractory Myeloma Patients: Melflufen

Apr 02, 2021
07:00PM - 08:00PM EDT
Online Event
Overview

A new treatment for multiple myeloma called melflufen (PEPAXTO®) was recently FDA-approved for relapsed or refractory multiple myeloma patients who have received at least four prior lines of therapy. Join us to hear Dr. Agne Paner of Rush University explain what the new therapy is, who qualifies for it, when it should be considered and how it works. Come with questions for the Q&A!

Agenda
07:00 PM
Introductions
Jenny Ahlstrom
Jenny introduces the new Myeloma Community Chapter, the event agenda, and our featured speaker, Dr. Agne Paner. 
07:05 PM
Presentation
Dr. Agne Paner
Dr. Paner explains what the melflufen is, who qualifies for it, and how it works. Come with questions! 
07:40 PM
Questions and Answers
Audience
Ask your questions about this new treatment to Dr. Paner! 
Speakers & Moderators
Healthtree contact Jennifer Ahlstrom

Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Healthtree contact Agne Paner, MD

Agne Paner, MD

Dr. Paner is an Associate Professor of Medicine in the Multiple Myeloma and Amyloidosis Program at Rush Medical College. Her research interests include clinical trials with innovative approaches to the treatment of patients with multiple myeloma and amyloidosis. She had hands-on experience in the HORIZON trial. She has been treating multiple myeloma for over 10 years and takes care of about 200 patients with multiple myeloma a year.